Description
BioMarin Crosses $1 Billion in Quarterly Revenue as Amicus Synergies Accelerate!
BioMarin Pharmaceutical Inc. reported third-quarter 2026 revenues exceeding $1 billion for the first time, reflecting a 32% year-over-year increase fueled by strong demand across its diversified portfolio. The metabolic conditions segment drove 44% revenue growth, with key contributions from Galafold and Pombility and Opfolda, generating over $200 million combined in the quarter. Notably, the integration of Amicus has delivered cost synergies ahead of schedule, supporting a targeted $220 million in non-GAAP savings by 2028. VOXZOGO revenues grew 12% year over year to $245 million amid a global patient increase of 17%, and the company anticipates a May 2027 PDUFA date for VOXZOGO’s potential approval for hypochondroplasia, poised to expand its footprint in skeletal conditions. New clinical-stage assets augmented BioMarin’s pipeline, including the addition of BMN-450, a Phase 1/2 investigational subcutaneous enzyme replacement therapy for Fabry disease designed to reduce treatment burden and potentially address a broader patient population than Galafold.



